AGRX Agile Therapeutics Inc.

0.57
-0.01  -2%
Previous Close 0.58
Open 0.59
Price To Book 0.64
Market Cap 19521513
Shares 34,248,268
Volume 296,568
Short Ratio 0.56
Av. Daily Volume 702,362

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Further CRL issued December 22, 2017. Noted May 18, 2018 that FDA will require further trials for resubmission to take place.
Twirla
Contraceptive patch

Latest News

  1. AGRX: Files Formal Dispute Resolution with the FDA
  2. Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs
  3. Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance
  4. AGRX: Determining a Path Forward Following Receipt of Meeting Minutes
  5. Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals
  6. Agile Therapeutics sinks after FDA feedback on contraceptive
  7. Consolidated Research: 2018 Summary Expectations for Verint, Mesabi Trust, Clearwater Paper, Agile Therapeutics, Community Trust, and Layne Christensen — Fundamental Analysis, Key Performance Indications
  8. Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy
  9. Corium International (CORI) Q2 2018 Earnings Conference Call Transcript
  10. AGRX: Waiting on Meeting Minutes from FDA; Planning for 2Q18 Twirla® NDA Resubmission
  11. Have Investors Priced In Agile Therapeutics Inc’s (NASDAQ:AGRX) Growth?
  12. Agile Therapeutics: 1Q Earnings Snapshot
  13. Agile Therapeutics Reports First Quarter 2018 Financial Results
  14. When Can We Expect A Profit From Agile Therapeutics Inc (NASDAQ:AGRX)?
  15. [$$] 3 Biotech Stocks a Pro Is Buying Now
  16. What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?
  17. Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?
  18. Agile Therapeutics reports 4Q loss